Research progress of CAR-T in the treatment of hepatocellular carcinoma / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
; (12): 146-150, 2022.
Article
en Zh
| WPRIM
| ID: wpr-932749
Biblioteca responsable:
WPRO
ABSTRACT
In recent years, chimeric antigen receptor-modified T-cell (CAR-T) immunotherapy, as a new idea of tumor immunotherapy, has been proved to be effective in hematological diseases. More and more studies have been focusing on this field. At present, some progress have been made in the treatment of hepatocellular carcinoma with CAR-T, but some problems such as solid tumor inherent barrier, tumor microenvironment, immune escape and specific tumor associated antigens still need to be further figure out. Nevertheless, CAR-T immunotherapy will provide a more cutting-edge treatment for hepatocellular carcinoma immunotherapy. In addition, the combination of CAR-T and other methods may also be the direction to be explored in the next step.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Hepatobiliary Surgery
Año:
2022
Tipo del documento:
Article